Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21268106 | 1.00 | SIGMAR1 (1.00) | SIGMAR1GAASMN1; SMN2HTR2AHTR2C | |
| SCHEMBL16197791 | 1.00 | SIGMAR1 (1.00) | SIGMAR1GAASMN1; SMN2HTR2AHTR2C | |
| SCHEMBL16197621 | 1.00 | SIGMAR1 (1.00) | SIGMAR1GAASMN1; SMN2HTR2AHTR2C | |
| SCHEMBL21268109 | 1.00 | SIGMAR1 (1.00) | SIGMAR1GAASMN1; SMN2HTR2AHTR2C | |
| SCHEMBL16197372 | 1.00 | SIGMAR1 (1.00) | SIGMAR1GAASMN1; SMN2HTR2AHTR2C | |
| SCHEMBL16197676 | 1.00 | SIGMAR1 (1.00) | SIGMAR1GAASMN1; SMN2HTR2AHTR2C | |
| SCHEMBL16197550 | 0.92 | SIGMAR1 (0.85) | SIGMAR1GAASMN1; SMN2ADAM10ERBB2 | |
| SCHEMBL16197396 | 0.89 | SIGMAR1 (0.80) | SIGMAR1GAASMN1; SMN2HTR2AHTR2C | |
| SCHEMBL21268107 | 0.87 | SIGMAR1 (1.00) | SIGMAR1GAASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL21278134 | 0.87 | SIGMAR1 (1.00) | SIGMAR1GAASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2989104-B1 | PYRAZINO[1,2-A]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE PHARMACEUTICALS SA (ES) | 2019-08-21 | — | — | EP | claimed |
| US-9963453-B2 | Substituted pyrazino[1,2-a]indoles as sigma receptor activity modulators | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-05-08 | — | — | US | claimed |
| US-20160075709-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-03-17 | — | — | US | claimed |
| EP-2989104-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-03-02 | — | — | EP | claimed |
| WO-2014173901-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-10-30 | — | — | WO | claimed |
| EP-2989104-B1 | PYRAZINO[1,2-A]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE PHARMACEUTICALS SA (ES) | 2019-08-21 | — | — | EP | disclosed |
| US-9963453-B2 | Substituted pyrazino[1,2-a]indoles as sigma receptor activity modulators | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-05-08 | — | — | US | disclosed |
| US-9963453-B2 | Substituted pyrazino[1,2-a]indoles as sigma receptor activity modulators | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-05-08 | — | — | US | disclosed |
| US-9963453-B2 | Substituted pyrazino[1,2-a]indoles as sigma receptor activity modulators | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-05-08 | — | — | US | disclosed |
| US-20160075709-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-03-17 | — | — | US | disclosed |
| US-20160075709-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-03-17 | — | — | US | disclosed |
| EP-2989104-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-03-02 | — | — | EP | disclosed |
| WO-2014173901-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075709-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | IDO1, TPH1, IDO2 | SIGMAR1 168/4885GAA 4048/4885SMN1; SMN2 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.